US FDA approves J&J's ketamine-based therapy to treat depression
1. FDA approves JNJ's Spravato for major depressive disorder treatment. 2. This approval enhances JNJ's product portfolio and market position.
FAQ
Why Bullish?
FDA approval often boosts stock prices due to market potential. Similar past approvals have led to stock increases.
How important is it?
The approval signifies a new revenue stream which can impact JNJ's market valuation. Positive reception from healthcare markets can further solidify JNJ's standing.
Why Long Term?
The introduction of a new treatment can yield sustained sales growth. Long-term patient adoption may influence ongoing revenue.